Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. The need for new asthma treatments
3. Poor asthma control in the real world
4. Asthma deaths and therapy (UK)
5. Managing mild asthma: SYGMA 1
6. Managing mild asthma: SYGMA 2
7. NOVEL-START study
8. GINA
9. Severe asthma
10. Severe asthma: inflammatory phenotypes
11. Unmet needs in asthma therapy
12. Targeting T2 (eosinophilic) inflammation
13. Interleukin-5 in asthma
14. Anti-IL-5 and asthma exacerbations
15. Benralizumab in severe asthma
16. Interleukin-4/13 in asthma
17. Dupilumab: severe asthma
18. Dupilumab in asthma
19. GATA-3 inhibition
20. TSLP and asthma
21. Anti-TSLP: severe asthma
22. IL-33 and asthma
23. DP2 antagonists in asthma
24. Fevipiprant in severe asthma
25. Targeting neutrophil inflammation
26. Anti-TNF in severe asthma
27. CXCR2 antagonist in severe asthma
28. IL-17 expression in asthma
29. Anti-IL-17R in asthma
30. Macrolide in severe asthma
31. New anti-inflammatory treatments
32. PDE4 inhibitors
33. Roflumilast in asthma
34. Tiotropium in poorly controlled asthma
35. Mast cell inhibitors
36. Masitinib in severe asthma
37. A cure for asthma?
38. Conclusions: new asthma treatments

Topics Covered

• Improvements in existing therapies have been the main approach
• New classes of drug in development
• Upcoming oral and inhaled therapies that target inflammation in asthma
• Patients with severe disease
• Inflammation in severe asthma is usually corticosteroid insensitive

Links

Series:

• Advances in Asthma

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Publication History

• Published on December 29, 2011
• Archived on September 29, 2021

Financial Disclosures

• Peter Barnes receives research grants from AstraZeneca and Boehringer-Ingelheim and is an advisor and/or gives talks for AstraZeneca, Boehringer-Ingelheim, Covis, Novartis, Pieris and Teva.